Matches in Nanopublications for { ?s ?p "[Exposure to a calmodulin antagonist significantly slows IMP accumulation during experimental energy imbalance in patients' cells to levels that are similar to those in untreated controls, implying that Ca2+-calmodulin is involved in erythrocyte AMP deaminase activation in familial phosphofructokinase deficiency.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- assertion description "[Exposure to a calmodulin antagonist significantly slows IMP accumulation during experimental energy imbalance in patients' cells to levels that are similar to those in untreated controls, implying that Ca2+-calmodulin is involved in erythrocyte AMP deaminase activation in familial phosphofructokinase deficiency.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Exposure to a calmodulin antagonist significantly slows IMP accumulation during experimental energy imbalance in patients' cells to levels that are similar to those in untreated controls, implying that Ca2+-calmodulin is involved in erythrocyte AMP deaminase activation in familial phosphofructokinase deficiency.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP547951.RARd6jH0GghuVJeMNITiY2Bc98FGZPPet3hO7rdLNS3ZM130_assertion description "[Exposure to a calmodulin antagonist significantly slows IMP accumulation during experimental energy imbalance in patients' cells to levels that are similar to those in untreated controls, implying that Ca2+-calmodulin is involved in erythrocyte AMP deaminase activation in familial phosphofructokinase deficiency.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP547951.RARd6jH0GghuVJeMNITiY2Bc98FGZPPet3hO7rdLNS3ZM130_provenance.
- NP794489.RAnUKeHwa2yJmSCo3EyOU0Md4kv-OyJlhYJ5iHzy8ggyM130_assertion description "[Exposure to a calmodulin antagonist significantly slows IMP accumulation during experimental energy imbalance in patients' cells to levels that are similar to those in untreated controls, implying that Ca2+-calmodulin is involved in erythrocyte AMP deaminase activation in familial phosphofructokinase deficiency.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP794489.RAnUKeHwa2yJmSCo3EyOU0Md4kv-OyJlhYJ5iHzy8ggyM130_provenance.
- NP509493.RAw28KMRqNLQRsgh5jBZio3PYL4zA2bwGz79ib_4AYJeM130_assertion description "[Exposure to a calmodulin antagonist significantly slows IMP accumulation during experimental energy imbalance in patients' cells to levels that are similar to those in untreated controls, implying that Ca2+-calmodulin is involved in erythrocyte AMP deaminase activation in familial phosphofructokinase deficiency.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP509493.RAw28KMRqNLQRsgh5jBZio3PYL4zA2bwGz79ib_4AYJeM130_provenance.
- NP547956.RAO1XUR4LXd-rCKLlKspPAShKSm-VoMVYYwhHTLKS0qbU130_assertion description "[Exposure to a calmodulin antagonist significantly slows IMP accumulation during experimental energy imbalance in patients' cells to levels that are similar to those in untreated controls, implying that Ca2+-calmodulin is involved in erythrocyte AMP deaminase activation in familial phosphofructokinase deficiency.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP547956.RAO1XUR4LXd-rCKLlKspPAShKSm-VoMVYYwhHTLKS0qbU130_provenance.